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ABSTRACT:
Cdk9 is a key elongation factor for RNA transcription and functions by 
phosphorylating the C-terminal domain of RNA polymerase II. Here we present 
direct evidence that cdk9 is important for cancer cell survival and describe the 
characterization of the potent cdk9 inhibitor CDKI-73 in primary human leukemia 
cells. CDKI-73 induced caspase-dependent apoptosis that was preceded by 
dephosphorylation of cdk9 and serine 2 of RNA polymerase II. CDKI-73 was more 
potent than the pan-cdk inhibitor flavopiridol and showed >200-fold selectivity 
against primary leukemia cells when compared with normal CD34+ cells. Furthermore, 
CDKI-73 was equipotent in poor prognostic sub-groups of leukemia patients and 
showed cytotoxic synergy with the nucleoside analog fludarabine. The Mechanism 
of synergy was associated with CDKI-73-mediated transcriptional inhibition of MCL1 
and XIAP that was maintained when used in combination with fludarabine. Our data 
present a strong rationale for the development of cdk9 inhibitors such as CDKI-73 
as anticancer therapeutics.
INTRODUCTION
A number of human cancers, including chronic 
lymphocytic leukemia (CLL), are associated with the 
over expression of anti-apoptotic BCL2 family proteins 
[1-3]. CLL is the most common leukemia in the western 
world and accounts for almost half of all leukemias in 
older adults [4]. It is characterized by the progressive 
accumulation of monoclonal CD5+ B-cells in lymphoid 
tissues, bone marrow and peripheral blood and by the 
resistance of neoplastic cells to apoptosis [5]. The most 
challenging aspect of the management of CLL is the 
treatment of relapsed patients [6] and given that most CLL 
patients who require treatment will develop resistance 
to conventional drugs, the identification of new CLL 
therapies remains a high priority. 
The molecular mechanisms that underpin drug 
resistance in CLL cells are likely to be complex, but the 
increased expression of anti-apoptotic proteins clearly 
contributes to this process[3]. MCL1, a member of the 
BCL2 family, is particularly associated with chemo-
resistance and poor prognosis [7, 8] suggesting that 
therapeutic strategies targeting this protein may be of 
particular value in CLL. Given the short half-life of MCL1 
[9], one strategy for targeting MCL1 is transient inhibition 
of transcription. 
Transcription initiation and elongation is regulated 
by the cyclin dependent kinases (cdk7 and cdk9), which 
phosphorylate the carboxy-terminal domain (CTD) of 
RNA polymerase II[10]. Cdk9 and its cyclin partner, 
cyclin T1, are highly expressed in CLL suggesting that 
it may play a role in the pathology of this disease [11, 
12]. Indeed, inhibition of these cdks by the cdk inhibitors 
flavopiridol, SNS-032 and R-roscovitine results in rapid 
depletion of MCL1 and the induction of apoptosis in 
primary CLL cells [13-15]. Although these pan cdk 
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inhibitors showed great promise in pre-clinical models, 
they have proven to have a narrow therapeutic window in 
clinical trials, with complications relating to scheduling 
and administration and significant side effect profiles [16-
18]. We therefore initiated a program of drug development 
to identify cdk9 inhibitors with more favorable drug-like 
properties and an improved therapeutic index. 
Here we provide proof-of-concept that cdk9 plays a 
key role in tumor cell survival as selective cdk9 inhibition, 
using an shRNA strategy, triggered CLL cell apoptosis 
confirming cdk9 as a potential anti-cancer therapeutic 
target. We also describe the preclinical evaluation of the 
potent cdk9 inhibitor, CDKI-73 in primary CLL cells and 
detail its potential as a clinical agent both as a single agent 
and in combination with the purine nucleoside analog 
fludarabine.
RESULTS
Cdk9 knockdown inhibits survival of MEC-1 cells 
and primary CLL cells 
As a first step, we set out to establish the biological 
consequences of specifically inhibiting cdk9. We silenced 
cdk9 expression using a lentiviral short hairpin RNA 
(shRNA) construct in the immortalized CLL cell line, 
MEC-1 [19] and in primary CLL cells freshly isolated 
from patients. Cdk9 silencing was most effective in the 
MEC-1 cell line (Figure 1A) and stable knockdown was 
possible in these cells to 20 % of empty vector controls. 
Furthermore, cdk9- MEC-1 cells showed significantly 
increased sensitivity to fludarabine when compared to 
empty vector and scrambled vector controls (Figure 
1B). Despite the technical challenges associated with 
genetic modification of primary CLL cells, short-term 
knockdown of cdk9 was also achieved in primary CLL 
cells to approximately 50% of empty vector controls 
(Figure 1C) and this resulted in a significant increase in 
spontaneous apoptosis (Figure 1D). Taken together, these 
results demonstrate that cdk9 inhibition has a biological 
consequence in CLL cells and confirm that cdk9 inhibition 
is a valid anticancer therapeutic strategy.
The novel cdk9 inhibitor, CDKI-73, shows 
preferential cytotoxicity in CLL cells 
We have recently reported the development 
of a novel class of 5-substituted 4-(thiazol-5-yl)-2-
(phenylamino)pyrimidines with cdk9 inhibitory activities 
[20, 21]. These inhibitors specifically target the cdk9-
ATP gatekeeper residue Ph30 and ribose-binding pocket 
and structure-activity relationship analysis revealed 
the importance of the 5C-group of pyrimidine core for 
cdk9 potency and selectivity [21]. Here, we report the 
biological evaluation of our lead compound CDKI-73 
(Figure 2A) that was selected on the basis of its biological 
potency and its excellent pharmacological properties. It 
exhibited a favorable pharmacokinetic profile with oral 
bioavailability of F = 56% following a single intravenous 
bolus dose at 2 mg/kg and an oral dose at 10 mg/kg in 
mice. All of the in vitro analyses were performed using 
primary CLL cells and the pan-cdk inhibitor flavopiridol 
was used as a comparator. CDKI-73 was cytotoxic 
to all of the CLL samples tested (n = 38) with a mean 
LD50 value of 0.08µM ± 0.10 µM following exposure 
to drug for 48h. In contrast, normal B-lymphocytes (n = 
10) and CD34+ normal bone marrow cells (n = 5) were 
significantly less susceptible to the cytotoxic effects 
of CDKI-73 (Figure 2B). The mechanism of CDKI-
73-induced cell killing was confirmed to be apoptosis 
(Figure 2C) and this was mediated via a dose-dependent 
induction in caspase-3 activation at an early time point 
(8h) following exposure to CDKI-73 (Figure 2D). The 
kinase inhibition profiles of CDKI-73 and flavopiridol 
were very similar (Figure 2E) but the notional therapeutic 
indices for the two agents were remarkably different with 
CDKI-73 showing significantly enhanced selectivity for 
CLL cells over normal B-lymphocytes and CD34+ bone 
marrow cells. The apparent discrepancy in these results 
may be explained, at least in part, by the recent finding 
that flavopiridol is also a DNA damaging agent [20] and 
that it induces ER stress and autophagy [22].  
Figure 1: Cdk9 knock-down in MEC-1 cells and 
primary CLL cells. In order to establish whether cdk9 is a 
valid therapeutic target, lentivirus containing cdk9 shRNA was 
produced. In the first instance (A) MEC-1 cells were infected 
with virus and following puromycin selection cells were cultured 
for 48h and cell viability assessed. (B) MEC-1 cells transfected 
with cdk9 shRNA showed significantly increased spontaneous 
apoptosis when compared with empty vector and scrambled 
sequence controls. (C) Next primary CLL cells were subjected 
to the same lentiviral infection protocol. Cdk9 was knocked 
down to approximately 50% of the empty vector control levels 
in these cells and this resulted in (D) a significant increase in 
spontaneous apoptosis. *P < 0.05, **P < 0.0001.
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CDKI-73 is equipotent in poor prognostic subsets 
and retains efficacy under pro-survival co-culture 
conditions
The in vitro cytotoxic effects of CDKI-73 were 
compared with flavopiridol and the purine nucleoside 
analog fludarabine. Under standard liquid culture 
conditions CDKI-73 was significantly more potent than 
flavopiridol and fludarabine (Figure 3A). Furthermore, we 
compared the in vitro effects of CDKI-73 and fludarabine 
in parallel co-culture experiments in which primary CLL 
cells were co-cultured with CD40L-expressing mouse 
embryonic fibroblasts; conditions known to be highly 
cytoprotective to CLL cells [23].  CDKI-73 retained 
cytotoxicity under these conditions whereas the cytotoxic 
effects of fludarabine were abrogated. Importantly, CDKI-
73 was equipotent in CLL cells derived from patients 
who had suffered clinical relapse following standard 
chemotherapy including three samples with a 17p deletion 
Figure 2: CDKI-73 shows selective toxicity to CLL cells (A) Chemical structure of 3-(5-fluoro-4-(4-methyl-2-
(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)benzenesulfonamide (CDKI-73). (B) Shows an example of overlaid 
sigmoidal dose-response curves for CDKI-73 in CLL cells, normal B-cells and normal CD34+ bone marrow. All cells were cultured in the 
presence of increasing concentrations of CDKI-73 for 48h. (C) CDKI-73 caused a dose-dependent increase in Annexin V positive cells and 
this was preceded by (D) a dose-dependent increase in caspase-3 activation after 24h in culture. (E) Table of the kinase inhibition profiles 
for CDKI-73 in comparison with flavopiridol together with LD50 values in primary CLL cells, normal B-cells and normal CD34+ bone 
marrow.
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(Figure 3B). In keeping with this finding, when we broke 
the CLL cohort down into prognostic subsets, none of 
the poor prognostic markers appeared to significantly 
impact upon the ability of CDKI-73 to induce apoptosis 
(Figure 3C). All of the data presented in this manuscript 
were derived from culture conditions supplemented with 
10% fetal bovine serum. However, given the unfavorable 
human plasma binding characteristics of flavopiridol 
[24], we compared the cytotoxic effects of CDKI-73 in 
culture conditions supplemented with 10% autologous 
human plasma. As expected, the addition of autologous 
plasma to flavopiridol-treated cultures resulted in a 
marked reduction in apoptosis (>2-fold) in all the samples 
tested (n = 7). Although CDKI-73 also showed reduced 
cytotoxicity under these conditions, the effects were much 
less pronounced (Figure 3D) suggesting that this agent 
might have superior bioavailability when compared to 
flavopiridol.
CDKI-73 inhibits the phosphorylation of serine 
2 of RNA polymerase II and MCL1 protein 
expression in CLL cells
We next investigated the molecular mechanisms 
that underpin the cytotoxic effects of CDKI-73 in CLL 
cells. Treatment of CLL cells with 0.1µM CDKI-73 for 
4h inhibited the phosphorylation of cdk9 and ser2 of 
RNA polymerase II (Figure 4A). Phosphorylation of ser2 
of RNA polymerase II is essential for RNA polymerase 
II-dependent transcription[25] and inhibition of this 
process has been shown to preferentially deplete labile 
proteins like MCL1. The importance of MCL1 protein 
expression has been previously shown in CLL and MCL1 
depletion is sufficient to induce CLL cell apoptosis[25]. 
Here we demonstrate that CDKI-73 induces a rapid loss 
of MCL1 protein (Figures 4A-4C) and this is mediated 
by significant inhibition at the level of gene transcription 
(Figure 4D).  However, this inhibition is not restricted 
to MCL1 as similar reductions in XIAP and CCND2 
were also observed following exposure to CDKI-73 for 
Figure 3: CDKI-73 is more potent than fludarabine and flavopiridol and is equipotent in samples derived from relapsed 
patients. (A) CDKI-73 was significantly more cytotoxic to CLL cells than flavopiridol and fludarabine. (B) CDKI-73 retained potency in 
samples derived from patients with relapsed disease (n = 7) and in three patient samples with a p53 deletion. (C) CDKI-73 was equipotent 
in samples derived from prognostic subsets of CLL patients. (D) Given the plasma binding characteristics of flavopiridol, the effects of 
CDKI-73 were determined in autologous plasma. Although CDKI-73 exhibited reduced potency when compared to cultures carried out in 
fetal bovine serum (n = 6), it was still able to induce apoptosis in the presence of autologous plasma and was significantly more active than 
flavopiridol. *P < 0.05, **P <0.0001.
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4h (Figure 4D). It is worthy of note that normal B-cells 
show significantly lower levels of transcription of MCL1 
and XIAP compared to CLL cells (Figure 4E) perhaps 
providing a rationale for the preferential toxicity of CDKI-
73 in leukemia cells.
CDKI-73 synergizes with fludarabine
Fludarabine-based treatment options are currently 
the standard of care for CLL patients without significant 
comorbidities. We therefore assessed the in vitro 
effects of combining CDKI-73 with fludarabine. The 
fixed molar ratio used in this study was determined 
experimentally. The ratios tested were constrained by the 
maximum clinically achievable dose of fludarabine and 
the relative potency of each agent. The most synergistic 
interaction was achieved using a fixed molar ratio of 
100:1 (fludarabine:CDKI-73) (Figure 5A). All of the 
samples tested (n = 10) showed synergy, with a median 
combination index of 0.71. Furthermore synergy was 
observed over the range of concentrations of drug used 
as shown in Figure 5B. In an attempt to understand 
the underlying molecular mechanisms for the synergy 
observed, we performed gene expression profiling of 
CLL cells treated with 10 µM fludarabine, 0.1 µM CDKI-
73 and the combination of the two agents (100:1). Gene 
expression changes were observed under all drug treatment 
conditions when compared with untreated controls. Figure 
5C shows the relative expression changes in genes known 
to be susceptible to RNA polymerase II inhibition. CDKI-
73 as a single agent down regulated MCL1, XIAP and 
CCND1 and CCND2. In contrast, fludarabine induced the 
expression of MCL1 but this induction was reversed by the 
Figure 4: CDKI-73 inhibits cdk9 phosphorylation, RNA polymerase II phosphorylation, MCL1 transcription and 
protein expression. Primary CLL cells were cultured in the presence of 0.1 μM CDKI-73 for 8h. (A) Western blots from two individual 
patients demonstrating inhibition of cdk9 phosphorylation, RNA polymerase II phosphorylation and MCL1 expression. (B) Overlaid 
histograms showing CDKI-73-mediated inhibition of MCL1 protein expression (C) MCL1 protein expression was consistently inhibited by 
CDKI-73 at 8h in all the primary CLL samples tested. Importantly, this change in MCL1 protein expression preceded evidence of apoptosis 
induction. (D) The inhibition of MCL1 protein was mirrored by the marked inhibition MCL1, XIAP and CCND2 transcription at 4h. (E) 
Primary CLL cells showed significantly elevated transcription of MCL1 and XIAP when compared to normal B-cells perhaps providing a 
rationale for the selectivity of CDKI-73 in CLL cells. **P < 0.0001.
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combination of CDKI-73 and fludarabine. Clearly other 
molecular mechanisms may also contribute to the synergy 
observed between these agents but the suppression of 
MCL1, XIAP and CCND1 and CCND2 seem likely to be 
Figure 5: CDKI-73 synergizes with fludarabine even on pro-survival CD40L co-culture. (A) Different molar ratios of 
fludarabine:CDKI-73 were tested on primary CLL cells in 48h cytotoxicity assays. The combination ratios were based on the LD50 values 
for each drug and the maximum tolerated dose of fludarabine in vivo. 100:1 was shown to give the strongest synergy in all the samples 
tested. (B) Synergy was observed at all the concentrations of drug combination tested. (C) Gene expression profiling revealed a potential 
mechanism for the synergy observed. CDKI-73 inhibited the transcription of MCL1, BCL2, XIAP and CCND1 and D2. In contrast, 
fludarabine induced MCL1, BCL2 and XIAP transcription providing a rationale for the drug resistance that commonly occurs following 
retreatment with fludarabine. Importantly, the combination of CDKI-73 and fludarabine showed a marked repression of MCL1, BCL2, 
XIAP and CCND1 and D2. We next tested the effect of the combination under pro-survival, CD40L-expressing co-culture conditions. (D) 
These conditions are known to induce marked resistance to fludarabine but synergy was retained when used in combination with CDKI-73. 
(E) Finally we used QRT-PCR to assess the relative expression of MCL1 under the various drug conditions with and without co-culture 
with CD40L-expressing mouse fibroblasts. In keeping with our gene expression profiling data, CDKI-73 repressed MCL1 both alone 
and in combination with fludarabine under all conditions. In contrast fludarabine induced MCL1, which was maintained under co-culture 
conditions. *P < 0.05, **P < 0.0001.
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major factors. 
CDKI-73 remains synergistic with fludarabine 
under pro-survival co-culture conditions
We have previously shown that co-culture of 
primary CLL cells with CD40L-expressing mouse 
embryonic fibroblasts completely abrogates the cytotoxic 
effects of fludarabine [23]. We therefore set out to 
determine whether the addition of CDKI-73 could reverse 
the drug resistance to fludarabine observed under these 
conditions. Although the combination index increased 
(median = 0.92), 8/10 samples tested showed cytotoxic 
synergy and the other two additive effects under these 
pro-survival culture conditions (Figure 5D). Analysis 
of the changes in transcription of MCL1 under these 
conditions confirmed that co-culture significantly induced 
MCL1 both in untreated CLL cells and cells exposed to 
fludarabine. In contrast, CDKI-73 significantly inhibited 
MCL1 transcription as a single agent and in combination 
with fludarabine (Figure 5E).
DISCUSSION
Cancer cells often appear to demonstrate oncogene 
addiction for anti-apoptotic proteins in order to maintain 
their survival advantage and resist apoptosis. One 
such cancer is chronic lymphocytic leukemia (CLL) 
in which over expression of BCL2 family proteins is a 
hallmark of the disease.[3] The expression of MCL1 is 
particularly associated with inferior clinical outcomes in 
this condition[7, 26-28]; a protein with a short half-life 
at both the mRNA and protein levels [9]. Cdk9 is a key 
regulator of RNA Polymerase II elongation and hence 
is particularly critical to the maintenance of expression 
of short-lived proteins [29]. Given the clear clinical 
importance of MCL1 in CLL, we rationalized that targeted 
inhibition of cdk9 might prove to be a useful therapeutic 
strategy in CLL and other cancers in which MCL1 is over 
expressed[30]. In the first instance, we tested our working 
hypothesis by silencing cdk9 using an shRNA approach. 
Our data provide the first direct evidence that specific cdk9 
inhibition can alter the survival characteristics of both an 
immortalized leukemia cell line and primary leukemia 
cells derived from patients. This new information provides 
a strong rationale for the development of small molecule 
inhibitors targeting cdk9.
In order to develop cdk9 inhibitors, we designed 
a series of substituted 4-(thiazol-5-yl)-2-(phenylamino)
pyrimidine derivatives with functional groups attached 
to the 5C-pyrimidine or 4C-thiazol ring moiety [20, 21, 
31]. These compounds target the cdk9-ATP gatekeeper 
residue Ph30 and ribose-binding pocket thereby conferring 
increased selectivity. In this paper we describe the 
biological characterization of one of our lead compounds, 
CDKI-73. This compound has potent cdk9 inhibitory 
activity and excellent pharmacological properties. 
Intriguingly, it has a similar cdk inhibitory profile to 
flavopiridol but manifests a remarkably different toxicity 
profile in primary CLL cells when compared to normal 
B-lymphocytes and normal CD34+ bone marrow cells; 
CDKI-73 is more than 200 times more selective than 
flavopiridol against CLL cells.  We hypothesize that this 
is caused, at least in part, by the off target DNA damaging 
properties of flavopiridol that we recently reported[20]. 
At the molecular level, CDKI-73 inhibited the 
phosphorylation of cdk9 and ser2 residue of RNA 
polymerase II. This resulted in the inhibition of MCL1 
protein expression which we confirmed using both 
Western blotting and flow cytometric quantification. 
This reduction in protein expression was mirrored by the 
inhibition of MCL1 transcription and consistent with the 
inhibition of RNA polymerase II, we demonstrated similar 
reductions in the transcription of CCND2 and XIAP at the 
same early time point. 
In addition to the promising potency and selectivity 
manifested by CDKI-73, we demonstrate here that it 
retains efficacy in primary CLL samples derived from 
poor prognostic subsets including those who had relapsed 
following fludarabine-based regimens. Given that most 
CLL patients respond to frontline therapy but later relapse 
[32], there is a clear need for novel therapeutics that can be 
used in this setting. It is worthy of note that p53 mutation/
deletion is more prevalent in relapsed patients [33] and 
here we show that CDKI-73 has similar potency in this 
context. Furthermore, CDKI-73 appears to have more 
favorable plasma binding characteristics than flavopiridol. 
Although replacement of FBS with autologous plasma 
resulted in the reduction in potency of CDKI-73, it was 
much less marked than that observed with flavopiridol.  
Given that fludarabine-based regimens still dominate 
the treatment of CLL [34-36], we assessed the effects of 
combining fludarabine with CDKI-73. We were able to 
demonstrate synergy between these two agents consistent 
with their distinct mechanisms of action. Furthermore, this 
was explored at the molecular level using gene expression 
profiling. As we predicted, CDKI-73 inhibited MCL1, 
BCL2, XIAP and CCND1 and CCND2. In contrast, 
fludarabine appeared to induce the expression of MCL1 
and XIAP offering a potential explanation for the in vitro 
and in vivo drug resistance that often ensues following 
exposure to fludarabine [23, 33]. The combination of 
CDKI-73 with fludarabine reversed the fludarabine-
mediated increase in MCL1 and XIAP providing a 
molecular rationale for the cytotoxic synergy observed. 
Furthermore, synergy was retained between these two 
agents even under pro-survival co-culture conditions. 
Fludarabine is largely ineffective under these conditions 
[23] (Figure 3A) indicating that CDKI-73 is capable of 
reversing fludarabine resistance. At the molecular level 
our data strongly suggest a role for MCL1-mediated 
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fludarabine resistance and so the ability of CDKI-73 to 
deplete the expression of this protein would appear to be 
key. Taken together, we provide compelling evidence that 
targeting cdk9 in CLL represents a promising therapeutic 
strategy both as a single agent and in combination with 
fludarabine.
METHODS
Cell isolation and culture
Peripheral blood samples from CLL patients (n 
= 38), normal age-matched peripheral blood (n = 10) 
and normal CD34+ bone marrow samples (n = 5) were 
obtained in accordance with the ethical approval obtained 
from South East Wales Research Ethics Committee 
(02/4806). Mononuclear cells were separated using Ficoll-
Hypaque (Sigma, Poole, UK) and autologous plasma 
was collected for use in some experiments. CLL B-cells 
and normal B-cells were purified by negative selection 
using CD3 microbeads. CD34+ bone marrow cells were 
purified by positive selection using CD34+ microbeads. 
All purification proceedures were carried out on an 
AutoMACS Pro separator (Miltenyi Biotec., Bisley, UK). 
Subsequently, 1x106/ml cells were maintained in RPMI 
medium supplemented with 10% fetal bovine serum 
(FBS), penicillin (50U/ml), streptomycin (50µg/ml) and 
recombinant human IL-4 (R and D Systems, Abingdon, 
UK) (5ng/ml). Normal Mouse embryonic fibroblast 
L-cells, either non-transfected (NTL) or L-cells expressing 
CD40 ligand (CD40L)[37] were used where indicated as 
feeder layers.
Chemical analysis  
Synthesis of a novel class of 5-substituted 
4-(thiazol-5-yl)-2-(phenylamino)pyrimidines have 
been recently described[21]. 3-(5-Fluoro-4-(4-methyl-
2-(methylamino)thiazol-5-yl)pyrimidin-2-ylamino)
benzenesulfonamide (CDKI-73) was obtained from 
3-guanidinobenzenesulfonamide and 3-(dimethylamino)-
2-fluoro-1-(4-methyl-2-(methylamino)thiazol-5-yl)
prop-2-en-1-one. mp 268 – 270 ºC. Anal. RP-HPLC: tR 
11.45 min, purity 99 %. 1H-NMR (DMSO-d6): δ 2.88 (d, 
3H, J = 4.8 Hz, CH3), 7.29 (s, 2H, NH2), 7.40 (d, 1H, 
J = 8.0 Hz, Ph-H), 7.47 (t, 1H, J = 8.0 Hz, Ph-H), 7.89 
(d, 1H, J = 8.0 Hz, Ph-H), 8.13 (br q, 1H, J = 4.8 Hz, 
NH), 8.25 (s, 1H, Ph-H), 8.47 (d, 1H, J = 3.2 Hz, Py-H), 
9.83 (s, 1H, NH). 13C-NMR (DMSO-d6): δ 19.43 (d, 
J = 5 Hz), 31.33, 109.97 (d, J = 8 Hz), 115.81, 118.78, 
121.89, 129.51, 141.46, 144.94, 145.97 (d, J = 25 Hz), 
147.63 (d, J = 12 Hz), 147.94 (d, J = 248 Hz), 155.66, 
156.04, 171.34. HR-MS (ESI+): m/z [M + H]+ calculated 
for C15H16FN6O2S2, 395.0760, found 395.0641. 
Flavopiridol and fludarabine were purchased from Sigma-
Aldrich (Poole, UK).
Lentiviral production and transduction of stable 
cell lines
Bacterial glycerol stocks containing the lentiviral 
plasmid vector pLKO.1-puro with shRNA inserts against 
CDK9 (495) along with an empty vector (EV) and a 
scrambled shRNA (SCR) controls were obtained from 
Sigma Aldrich (Poole, UK). For lentiviral production, 
293T cells were transfected with complexes comprising 
1µg lentiviral shRNA plasmid (495, EV or SCR), 0.75 
µg P8∆91 plasmid, and 0.5 µg pMD2G plasmid using the 
Effectene reagent (Qiagen) according to the manufacturer’s 
instructions. Transfected 293T cells were incubated at 
37oC for 48h before the resulting lentiviral particles were 
harvested by centrifugation and concentrated using the 
Clontech Lenti-X concentrator kit (Lonza, Wokingham, 
UK). Concentrated virus was added to MEC-1 cells and 
incubated for 48h. Lentivirus-transduced cells were then 
selected by addition of puromycin (1 µg/ml) to the culture 
for two weeks. Subsequently, the relative sensitivity to 
fludarabine of EV, SCR and 495 transduced cells was 
assessed by flow cytometry.
Lentiviral modulation of cdk9 in primary CLL 
cells
Primary CLL cells were incubated with the 
transfected 293T cells for 48h before cell viability was 
measured and protein harvested for immunoblotting. 
Apoptotic effects of CDKI-73 and fludarabine on 
primary CLL cells
Cells were treated with CDKI-73 (0-1µM) for 48h 
before cell viability was determined by flow cytometry 
using Annexin V and propidium iodide as previously 
described[23]. In parallel experiments CLL cells were 
also treated with 0.1µM CDKI-73 for 4h and cells 
were harvested for protein extraction and subsequent 
immunoblotting.
Protein isolation and immunoblotting
CLL cells were washed with PBS and lysed by 
resuspension in lysis buffer (HEPES 50 mM, sodium 
fluoride 5 mM, iodoacetamide 5 mM, sodium chloride 
75mM, NP40 1%, PMSF 1 mM, sodium orthovanadate 
1 mM, protease inhibitors (Sigma) 1%, phosphatase 
inhibitor cocktail 2 (Sigma) 1%, phosphatase inhibitor 
cocktail 3 (Sigma) for 30 minutes at 4oC followed 
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by centrifugation at 16 000 x g.  Clarified lysates were 
subjected to electrophoresis using NuPage precast 4-12% 
Bis-Tris gels (Invitrogen, Paisley, UK) followed by 
transfer to PVDF membranes (GE Healthcare UK Ltd, 
Little Chalfont, UK). Immunoblotting was performed with 
antibodies against cdk9, tubulin (Abcam, Cambridge, UK), 
phospho-cdk9, MCL1 (New England Biolabs, Hitchin, 
UK) and RNA polymerase II phospho-ser2 (Active Motif, 
Rixensart, Belgium). 
Determination of synergy between cdk9 inhibitors 
and fludarabine
CDKI-73 was combined with fludarabine at an 
experimentally determined fixed molar ratio of 100:1 
(fludarabine:CDKI-73). CLL cells were treated with both 
cdk inhibitors and fludarabine alone and in combination 
to determine whether there were synergistic interactions 
between the two agents. Synergy was calculated according 
to the Chou and Talalay median effect method[38]. 
Real-time reverse transcription-PCR
Untreated cells and cells treated with CDKI-73, 
fludarabine or their combination (fludarabine: CDKI-73, 
100:1) for 4h. 5x106 CLL cells were re-suspended in 1ml 
Trizol reagent and RNA was extracted using chloroform 
and isopropanol. RNA (1μg) was used in a 20μL reverse 
transcription (RT) reaction[23]. SYBR Green technology 
(Roche Diagnostics, Burgess Hill, UK) was used to 
quantify the amount of RNA present in each sample using 
primer pairs for CCND2 (cyclin D2), MCL1, XIAP and 
RPS14. All primers were purchased from Eurogentec Ltd 
(Southampton, UK). The amount of mRNA was assessed 
using real-time RT-PCR using the LightCycler System 
(Roche Diagnostics). The amount of RPS14 mRNA was 
quantified in all samples as an internal house-keeping 
control, and the results of the real-time RT-PCR were 
expressed as normalized target gene values (e.g. the ratio 
between MCL1 and RPS14 transcripts calculated from 
the crossing points of each gene). All experiments were 
performed in duplicate. Total RNA was amplified using the 
following primers:CCND2: 5′- tcattgagcacatccttcgcaagc-3′ 
(forward) and 5′- ggcaaacttgaagtcggtagcaca-3′ 
(reverse);MCL1: 5′-aaaagcaagtggcaagagga-3′ (forward) 
and 5′-ttaatgaattcggcgggtaa-3′ (reverse);XIAP: 
5′-tgggacatggatatactcagttaacaa-3′(forward) and 
5′-gttagccctcctccacagtgaa-3′ (reverse);RPS14: 
5′-ggcagaccgagatgaactct-3′ (forward) and 
5′-ccaggtccaggggtcttggt-3′ (reverse).
Microarray procedures
The detailed protocol for sample preparation and 
microarray processing is available from Affymetrix (http://
www.affymetrix.com). Briefly, total RNA was extracted 
from CLL cells treated with 0.1µM CDKI-73, 10µM 
fludarabine or the two drugs in combination for 4h. First 
strand complementary DNA (cDNA) was synthesized 
from 5 µg total RNA using a T7-(dT)24 primer (Genset 
Corp, San Diego, CA, USA) and reverse-transcribed with 
the Superscript Double-Stranded cDNA Synthesis Kit 
(Invitrogen Life Technologies, San Diego, CA, USA). 
After second strand synthesis, the resulting cDNA was 
subjected to an in vitro transcription reaction using a 
Bioarray kit (Enzo Diagnostics, New York, NY, USA) 
to generate biotinylated cRNA. This was subsequently 
fragmented and hybridized to the Affymetrix U133 2.0 
Gene Chips. After hybridization, each microarray was 
washed, stained and scanned with an argon-ion confocal 
laser, with excitation at 488 nm and detection at 570 
nm. The data discussed in this publication have been 
deposited in NCBI’s Gene Expression Omnibus and 
are accessible through GEO Series accession number 
GSE48258 (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE48258).
Statistical Analysis
The significance of differences between 
experimental conditions was determined using the 
Student’s t-test for paired and unpaired observations. 
All data was confirmed as Gaussian or a Gaussian 
approximation using the omnibus K2 test. To assess the 
interaction between agents, the median effect method was 
employed using CalcuSyn software (CalcuSyn; Biosoft 
International, Ferguson, MO). The combination index 
was calculated for the two-drug combination using an 
experimentally determined fixed concentration ratio. 
Combination index values < 1.0 indicated a synergistic 
interaction. Affymetrix gene expression data were 
processed using MADRAS software (Developed by 
Peter Giles, Cardiff University). P values < 0.05 were 
considered significant.
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